ClinicalTrials.gg
CompletedNCT00840580Updated Jul 23, 2012

Effect on Wound Healing of Vigamox Versus Cravit

A Phase 4 interventional study of Moxifloxacin 0.5% ophthalmic solution (Vigamox) and Levofloxacin 0.5% ophthalmic solution (Cravit) in Cataract Extraction, sponsored by Alcon Research. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2012-07-23.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing moxifloxacin in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Cataract.

Enrollment
4th of 12
79 · median 62
Started
2009
with 1 other
Phase 4
9 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
4 of 12
Alcon Research

Among the 12 studies testing moxifloxacin in Cataract, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is one of 9 in phase 4, and was the 3rd registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 12 studies testing moxifloxacin in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About moxifloxacin

Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing moxifloxacin in Cataract, or all of them as a file.
02

Study summary

The purpose of this study was to compare the effects of Vigamox and Cravit on corneal wound healing after cataract surgery.

03

Conditions studied

  • Cataract Extraction

Keywords

  • Cataract, Cornea, Vigamox, Cravit
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of any race and either sex, and over the age of 18, who are scheduled for removal of a cataract and implantation of a posterior chamber intraocular lens using clear corneal incisions or near-clear corneal incisions.
  • Intraocular pressure (IOP) readings, treated or untreated, less than or equal to 20 mmHg prior to surgery. Glaucoma patients are eligible if an ocular hypotensive agent (only one) controls their IOP.
  • Other than cataracts, have normal healthy eyes as determined by the ophthalmic examination and case history.
  • Subconjunctival injections right after cataract surgery are allowed.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Any cataract wound that is stitched or any gross abrasion of the epithelium after removal of a cataract and implantation of a posterior chamber intraocular lens.
  • Fluorescein staining of the cornea at baseline.
  • History or evidence of ocular or systemic disease, which would preclude participation in this study. Examples could include disease affecting the cornea as well as any corneal dystrophies.
  • History of ocular inflammatory disease, ocular herpes infection, iritis, uveitis, or Sjögren's syndrome.
  • Known or suspected allergy or to levofloxacin or any related medicines, such as cinoxacin (Cinobac), ciprofloxacin (Cipro or Ciloxan), norfloxacin (Chibroxin or Noroxin), ofloxacin (Floxin), or nalidixic acid (NegGram), preservatives, dyes, or any components of the study medication.
  • Treatment for an ocular infection within 30 days prior to study entry.
  • Use of topical or systemic within 7 days prior to study entry.
  • Use of topical anti inflammatory drugs within 7 days prior to study entry.
  • Pregnancy, nursing/lactation, or inadequate methods. Oral contraceptives are allowed.
  • Patients with uncontrolled diabetes and/or diabetic retinopathy.
  • No ointment is used after cataract surgery.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Vigamox

    One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.

    Drug: Moxifloxacin 0.5% ophthalmic solution (Vigamox)

  • Active comparator
    Cravit

    One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.

    Drug: Levofloxacin 0.5% ophthalmic solution (Cravit)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients with epithelial defect

    The eye was imaged. An epithelial defect was defined as a non-continuous epithelium. The eye was considered healed when the defect was no longer visible.

    Time frame: Day 1, Day 2, Day 3, Day 10

07

Study locations

1 site
  • Seoul, 120-725, Korea, Republic of
08

References and documents

Publications

  • Han KE, Chung WS, Kim TI, Kim S, Kim T, Kim EK. Epithelial wound healing after cataract surgery comparing two different topical fluoroquinolones. Yonsei Med J. 2014 Jan;55(1):197-202. doi: 10.3349/ymj.2014.55.1.197. PubMed 24339307 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009 and a primary completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2009
First posted
Feb 10, 2009
Start
Jan 2009
Primary completionActual
Sep 2009
Last update
Jul 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00840580
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Feb 10, 2009
Start date
Jan 2009
Primary completion
Sep 2009
Last update
Jul 23, 2012

Study contacts

Eung Kweon Kim, MD/PhD
principal investigator · Severance Hospital, Yousei University College of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion